(Q42802043)

7 November 2017

Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates (English)

1 reference

7 November 2017

Astriab-Fisher A

1

1 reference

7 November 2017

Sergueev DS

2

1 reference

7 November 2017

Fisher M

3

1 reference

7 November 2017

Shaw BR

4

1 reference

7 November 2017

Juliano RL

5

1 reference

7 November 2017

language of work or name

English

0 references

publication date

1 July 2000

1 reference

7 November 2017

Biochemical Pharmacology

1 reference

7 November 2017

60

1 reference

7 November 2017

1

1 reference

7 November 2017

83-90

1 reference

An overview of progress in antisense therapeutics

7 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900310-5

Antisense oligonucleotides: towards clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900310-5

Gene inhibition using antisense oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900310-5

Antisense oligonucleotides as therapeutic agents--is the bullet really magical?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900310-5

7 January 2021

Antisense comes of age

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900310-5

P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900310-5

P-glycoprotein, multidrug resistance and tumor progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900310-5

Reversal of multidrug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900310-5

Is p-glycoprotein a potential target for reversing clinical drug resistance?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900310-5

A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900310-5

Ribozyme-mediated reversal of the multidrug-resistant phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900310-5

Modulation of P-glycoprotein-mediated multidrug resistance by monoclonal antibodies, immunotoxins or antisense oligodeoxynucleotides in kidney carcinoma and normal kidney cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900310-5

Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900310-5

Novel cationic amphiphiles as delivery agents for antisense oligonucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900310-5

A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900310-5

Tat-mediated delivery of heterologous proteins into cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900310-5

Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900310-5

A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a retro-inverso delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900310-5

Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900310-5

Design of carrier peptide-oligonucleotide conjugates with rapid membrane translocation and nuclear localization properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900310-5

A new vector using the human multidrug resistance gene as a selectable marker enables overexpression of foreign genes in eukaryotic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900310-5

Efficient methods for attachment of thiol specific probes to the 3'-ends of synthetic oligodeoxyribonucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900310-5

Reassessment of Ellman's reagent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900310-5

A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell Nucleus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900310-5

PAMAM dendrimers as delivery agents for antisense oligonucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900310-5

Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900310-5

The contrasting roles of ICE family proteases and interleukin-1beta in apoptosis induced by trophic factor withdrawal and by copper/zinc superoxide dismutase down-regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900310-5

10.1016/S0006-2952(00)00310-5

7 January 2021

Identifiers

DOI

1 reference

7 November 2017

1 reference